The AYUSH Ascendancy, Budget 2026, the India-EU FTA, and the Unresolved Battle Over India’s Medical Future

The AYUSH Ascendancy, Budget 2026, the India-EU FTA, and the Unresolved Battle Over India’s Medical Future

For decades, India’s traditional systems of medicine—Ayurveda, Yoga, Unani, Siddha, and Homoeopathy—occupied a curious, often contested space in the nation’s healthcare firmament. They were revered as cultural heritage, practised by millions, yet perpetually relegated to the periphery of “mainstream” medicine. They received fraction of the funding allocated to allopathy, their practitioners were denied the prestige accorded to MBBS doctors, and their products faced suspicion in Western markets. The Union Budget 2026-27, however, marks a decisive break from this historical ambivalence. With a record allocation of ₹4,408 crore, the establishment of three new All-India Institutes of Ayurveda (AIIA) modelled on the AIIMS template, a 66% hike for the National AYUSH Mission, and a suite of digital and quality infrastructure initiatives, the government has signalled that AYUSH is no longer a marginal adjunct to India’s healthcare system but a central pillar of its medical sovereignty and global outreach. Crucially, this domestic push is complemented by a transformative external development: the India-EU Free Trade Agreement (FTA) , which, for the first time, provides a legal and regulatory framework for Indian AYUSH practitioners, wellness centres, and pharmaceutical products to access the vast European market. Together, these twin developments represent the most significant expansion of AYUSH’s mandate since the ministry’s creation in 2014. Yet, they also intensify a long-simmering, unresolved conflict—between tradition and science, between regulation and innovation, and between the Indian Medical Association’s (IMA) fierce defence of allopathic exclusivity and the state’s assertion of medical pluralism.

Part I: The Budget Bonanza—Institutionalising AYUSH

The headline numbers from the 2026-27 Budget are striking. AYUSH’s total allocation has more than doubled from ₹2,122 crore in 2020-21 to ₹4,408 crore in 2026-27. This is not incremental growth; it is exponential acceleration.

1. Three New All-India Institutes of Ayurveda (AIIA):
The decision to establish three new AIIAs, on the model of the All India Institute of Medical Sciences (AIIMS), is conceptually significant. AIIMS is not merely a hospital; it is India’s premier institution for tertiary care, research, and medical education. By explicitly invoking the AIIMS analogy, the government signals that these new AYUSH institutes are intended to be centres of excellence, not peripheral dispensaries. They will treat complex cases, conduct high-level scientific research on traditional medicine, and train the next generation of Ayurvedic physicians. This institutionalises AYUSH within the same aspirational framework as allopathy.

2. National AYUSH Mission (NAM) Expansion:
The 66% hike in NAM’s budget, to ₹1,300 crore, is directed at three specific objectives:

• Modernisation: Upgrading existing AYUSH hospitals and dispensaries with contemporary infrastructure.

• Co-location: Placing AYUSH clinics inside existing allopathic hospitals, facilitating integrated care and cross-referral.

• Preventive Health: Shifting the focus from curative treatment to wellness and disease prevention—an area where traditional systems claim distinct advantage.

3. Quality and Digital Infrastructure:
The budget allocates funds to upgrade AYUSH pharmacies and drug-testing laboratories, addressing a long-standing criticism regarding the inconsistent quality and safety of Ayurvedic formulations. Concurrently, the introduction of Bharat-VISTAAR, a multilingual AI assistant for farmers cultivating medicinal plants, aims to strengthen the supply chain at its very root—providing real-time advice on cultivation practices, market prices, and export certification protocols.

Part II: The EU FTA—A Passport to the World

If the budget addresses domestic infrastructure, the India-EU Free Trade Agreement (FTA) , finalised a week before the budget, addresses international market access. For the AYUSH sector, this is arguably the more transformative development.

1. Professional Mobility:
Historically, Indian AYUSH practitioners seeking to work in Europe faced an insurmountable barrier: their degrees were not recognised by European member states. Under the FTA, in EU countries that do not specifically regulate traditional medicine, Indian practitioners can now offer their services using qualifications obtained in India. This opens a significant, albeit not unlimited, pathway for professional migration and service export.

2. Commercial Establishment:
The FTA provides Indian companies with a legally guaranteed right to establish wellness centres, Ayurvedic clinics, and AYUSH hospitals across the EU’s 27 member states. Crucially, it includes a stabilisation clause, ensuring that any subsequent regulatory changes will not arbitrarily disrupt existing investments. This provides the legal certainty essential for long-term commercial commitment.

3. Regulatory Recognition:
Perhaps the most technical but consequential provision concerns mutual recognition of conformity assessment. An Ayurvedic supplement tested for safety and heavy metal content in an accredited Indian laboratory will now be presumptively accepted by European customs authorities. This significantly reduces duplication, cost, and time-to-market.

4. Intellectual Property Protection:
The FTA formally recognises India’s Traditional Knowledge Digital Library (TKDL) as a prior art database. This prevents European companies from patenting formulations that are already documented in Indian traditional texts—a form of biopiracy that has historically plagued the sector.

Part III: The Unresolved Controversy—Is AYUSH Scientific?

For all the budgetary enthusiasm and diplomatic triumph, a fundamental question remains unanswered: Is AYUSH treatment scientific? And the corollary: Should AYUSH practitioners be permitted to practise allopathic medicine?

The Indian Medical Association (IMA) and its allies have consistently answered both questions in the negative. Their critique rests on several pillars:

1. The Evidence Deficit:
Modern allopathic medicine is built on the edifice of the randomised controlled trial (RCT) —a methodology designed to eliminate bias, control for placebo effects, and establish causal efficacy. Many AYUSH treatments, by contrast, derive their authority from ancient texts and centuries of observational practice. While this is not inherently invalid, it does not meet the evidentiary thresholds required for regulatory approval in most Western jurisdictions. The IMA argues that allowing AYUSH practitioners to prescribe treatments that lack robust RCT evidence exposes patients to unknown risks.

2. The Heavy Metal Problem:
Certain traditional Ayurvedic formulations, particularly Rasa Shastra preparations, intentionally include metals such as lead, mercury, and arsenic, which are subjected to elaborate purification processes (shodhana) intended to render them non-toxic and therapeutically active. However, health advisories from Australia, the United States, and New Zealand have documented cases of lead poisoning linked to imported Ayurvedic products. Critics argue that until India can guarantee the consistent safety and purity of exported formulations, the heavy metal question will remain a reputational liability.

3. Mixopathy and Surgical Practice:
The most explosive controversy concerns “mixopathy” —the state-sanctioned blurring of boundaries between traditional and modern medicine. In 2020, the Central Council of Indian Medicine (CCIM) authorised postgraduate Ayurveda students to be trained in 58 surgical procedures, including general surgery, obstetrics, and gynaecology. The IMA condemned this as “legalised quackery,” arguing that surgery is a complex discipline requiring comprehensive training in anatomy, anaesthesia, asepsis, and perioperative care—elements insufficiently covered in AYUSH curricula. The controversy reignited in 2025 when the Andhra Pradesh government permitted Ayurveda practitioners to independently perform these surgeries. Nationwide protests by allopathic doctors followed, and legal challenges are currently pending before the Supreme Court.

4. Allopathic Prescription:
A parallel friction point concerns the practice of AYUSH doctors prescribing allopathic medicines—antibiotics, steroids, antihypertensives—for which they have not been formally trained. Several state governments have issued executive orders prohibiting the import or sale of such drugs by non-allopathic practitioners, creating a patchwork of inconsistent regulation.

Part IV: The State’s Response—Pluralism as Policy

The government’s response to these critiques is not defensive; it is assertive. Its position, articulated through budget allocations, FTA negotiations, and regulatory reforms, rests on four principles:

1. Integration, Not Subordination:
The state rejects the hierarchical model that places allopathy at the apex and relegates traditional systems to the base. Instead, it advocates medical pluralism—a system where multiple streams of knowledge coexist, cross-fertilise, and are made accessible to patients based on their preferences and needs.

2. Upgradation, Not Abandonment:
The substantial investment in AYUSH research infrastructure, drug testing laboratories, and educational institutions is a bet that traditional systems can be modernised without being Westernised. The goal is to subject Ayurvedic formulations to rigorous scientific scrutiny using contemporary tools, while retaining their philosophical integrity.

3. Standardisation for Export:
The FTA’s emphasis on mutual recognition of lab results and TKDL protection reflects a strategic shift: India aspires to be not just a producer of traditional medicine but a global standard-setter. The upgrade of the WHO Global Traditional Medicine Centre in Jamnagar, explicitly endorsed in the budget, is central to this ambition.

4. Addressing Legitimate Concerns:
The government has not been entirely unresponsive to criticisms. The budget’s focus on upgrading drug-testing laboratories directly addresses the heavy metal contamination issue. The emphasis on co-location rather than substitution suggests an evolving, cautious approach to integration.

Part V: The Road Ahead—Opportunities and Perils

The AYUSH sector stands at an inflection point. The domestic resource envelope has expanded dramatically. The international market access barrier has been significantly lowered. The institutional architecture—AIIAs, NAM, Pharmacopoeia Commission, WHO Centre—is being strengthened. Yet, three fundamental challenges remain unresolved:

1. The Evidence Challenge:
India cannot demand that the world accept AYUSH treatments on faith. It must invest heavily in high-quality, independent clinical trials that meet international standards. This requires not just funding, but cultural change within AYUSH institutions—a willingness to subject cherished formulations to the risk of falsification.

2. The Regulatory Challenge:
The current system, where AYUSH drug regulation is separate from allopathic drug regulation, creates perverse incentives. A unified, science-based, risk-proportionate regulatory framework for all therapeutic products—regardless of their historical origin—is urgently needed.

3. The Scope-of-Practice Challenge:
The Supreme Court will eventually adjudicate the legality of AYUSH practitioners performing surgery and prescribing allopathic drugs. Whatever the verdict, a clear, nationally consistent, evidence-based scope-of-practice framework is essential. Leaving this to state-level executive orders invites chaos, litigation, and patient harm.

Conclusion: Between Tradition and Evidence

The Budget 2026-27 and the India-EU FTA represent a watershed moment for AYUSH. They reflect a government convinced that India’s traditional medical systems are not merely cultural artefacts to be preserved in museums but living, evolving knowledge traditions capable of contributing to global health.

Yet, the scepticism of the IMA and its allies is not merely professional territoriality. It reflects a genuine, ethically serious concern about patient safety, scientific rigor, and regulatory integrity. The accusation of “quackery” is harsh, but it cannot be dismissed with rhetoric alone.

The path forward lies not in the victory of one camp over the other, but in a mature, evidence-based, institutionally robust synthesis. AYUSH must embrace the tools of modern science—RCTs, toxicology screening, pharmacovigilance—without losing its philosophical soul. Allopathy must acknowledge that medical pluralism is not a threat but an enrichment, provided it operates within clearly defined, rigorously enforced safety boundaries.

India has chosen to bet big on AYUSH. The bet is not irrational; the sector possesses genuine competencies, a massive trained workforce, and a cultural resonance that allopathy cannot replicate. But bets must be validated. The coming years will determine whether this bet pays off—or whether the gap between ambition and evidence remains unbridgeable.

Q&A: AYUSH Budget 2026 and the India-EU FTA

Q1: What are the three most significant budgetary allocations for AYUSH in 2026-27, and what is their strategic intent?

A1: The three most significant allocations are:

1. Three new All-India Institutes of Ayurveda (AIIA): Modelled on AIIMS, these institutions are intended to be centres of excellence for tertiary care, high-level research, and postgraduate education. Strategic intent: to create visible, prestigious institutions that signal AYUSH’s parity with allopathy.

2. 66% hike in National AYUSH Mission (NAM) budget to ₹1,300 crore: Directed at modernising infrastructure, co-locating AYUSH clinics within allopathic hospitals, and shifting focus to preventive health. Strategic intent: to integrate AYUSH into the mainstream public health system and expand its reach beyond urban, affluent consumers.

3. Upgradation of AYUSH pharmacies and drug-testing laboratories: Addresses the long-standing criticism of inconsistent quality and heavy metal contamination. Strategic intent: to build trust in AYUSH products domestically and meet international regulatory standards for export.

Q2: How does the India-EU FTA specifically address the four key barriers Indian AYUSH practitioners and companies have historically faced in Europe?

A2: The FTA addresses four distinct barriers:

1. Professional Recognition: In EU countries without specific regulation of traditional medicine, Indian AYUSH practitioners can now practise using their Indian qualifications. Previously, non-recognition of degrees was an absolute barrier.

2. Right of Establishment: Indian companies now have a legally guaranteed right to open wellness centres and clinics across the EU, with a stabilisation clause preventing sudden regulatory reversals. Previously, they operated in a legal grey area.

3. Mutual Recognition of Lab Results: An Ayurvedic supplement tested in an accredited Indian laboratory will be presumptively accepted by European customs. Previously, duplicate testing in EU labs added significant cost and delay.

4. IP Protection: Formal recognition of India’s Traditional Knowledge Digital Library (TKDL) as prior art prevents European companies from patenting formulations already documented in Indian texts. This directly counters biopiracy.

Q3: What is the “mixopathy” controversy, and why has it led to legal challenges before the Supreme Court?

A3: “Mixopathy” is a pejorative term used by critics to describe the state-sanctioned blurring of boundaries between traditional and allopathic medical practice. The specific controversy centres on two issues:

1. Surgical Practice: In 2020, the Central Council of Indian Medicine authorised postgraduate Ayurveda students to be trained in 58 surgical procedures, including general surgery. The Indian Medical Association (IMA) condemned this, arguing that surgery requires comprehensive training in anatomy, anaesthesia, asepsis, and perioperative care—areas insufficiently covered in AYUSH curricula. In 2025, the Andhra Pradesh government permitted Ayurveda practitioners to independently perform these surgeries, triggering nationwide protests and legal challenges.

2. Allopathic Prescription: The practice of AYUSH doctors prescribing allopathic drugs (antibiotics, steroids) for which they lack formal training is another flashpoint. Several states have issued conflicting executive orders on this issue.

The matter is now before the Supreme Court, which must adjudicate the constitutional validity and scientific defensibility of expanding AYUSH’s scope of practice.

Q4: What are the principal scientific criticisms levelled against AYUSH by the Indian Medical Association and international health advisories?

A4: The principal criticisms are:

1. Evidentiary Deficit: Many AYUSH treatments derive authority from ancient texts and observational history, not from randomised controlled trials (RCTs) —the gold standard for establishing causal efficacy in modern medicine. Critics argue that tradition is not evidence.

2. Heavy Metal Contamination: Certain traditional Ayurvedic formulations intentionally include metals (lead, mercury, arsenic) subjected to purification processes (shodhana). However, health advisories from Australia, the US, and New Zealand have documented cases of lead poisoning linked to imported Ayurvedic products. Critics argue that until India can guarantee consistent safety, these products pose unacceptable risks.

3. Lack of Standardisation: Unlike allopathic drugs, which are chemically uniform and quality-controlled, many AYUSH formulations vary significantly between manufacturers, batches, and even individual preparations.

4. Scope Creep: The expansion of AYUSH practitioners into surgical and allopathic prescription domains is criticised as “legalised quackery” —practising beyond one’s competence.

Q5: What are the most critical unresolved challenges that will determine whether the current AYUSH expansion succeeds or falters?

A5: Three unresolved challenges are decisive:

1. The Evidence Challenge: India cannot demand international acceptance of AYUSH on faith. It must invest in high-quality, independent clinical trials meeting global standards. This requires not just funding, but a cultural shift within AYUSH institutions—willingness to subject cherished formulations to rigorous testing and accept falsification.

2. The Regulatory Challenge: The current bifurcated system (separate drug regulators for allopathy and AYUSH) creates perverse incentives and inconsistent standards. A unified, science-based, risk-proportionate regulatory framework for all therapeutic products is urgently needed.

3. The Scope-of-Practice Challenge: The Supreme Court must provide clarity. But beyond the verdict, India needs a clear, nationally consistent, evidence-based scope-of-practice framework defining what AYUSH practitioners can and cannot do. Leaving this to state-level executive orders invites chaos, litigation, and patient harm.

4. The Quality Assurance Challenge: The budget’s allocation for upgrading drug-testing labs is welcome, but implementation is key. India must build a credible, transparent, and enforceable system for certifying the safety and consistency of AYUSH products, both for domestic consumption and export. Without this, the EU FTA’s market access provisions cannot be fully realised.